

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Umeclidinium-Vilanterol (Anoro Ellipta)

#### Notes:

- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

**Initiation (new start) criteria:** Non-formulary **umeclidinium bromide and vilanterol trifenate (Anoro Ellipta)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed a trial of tiotropium-olodaterol (Stiolto Respimat), or patient has an allergy or intolerance\* to tiotropium and/or olodaterol.

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary **umeclidinium bromide and vilanterol trifenate (Anoro Ellipta)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed a trial of tiotropium-olodaterol (Stiolto Respimat), or patient has an allergy or intolerance\* to tiotropium and/or olodaterol.

**Continued use criteria for patients stable on the medication:** Non-formulary **umeclidinium bromide and vilanterol trifenate (Anoro Ellipta)** will continue to be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed a trial of tiotropium-olodaterol (Stiolto Respimat), or patient has an allergy or intolerance\* to tiotropium and/or olodaterol.